Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

7 results about "Acute renal failures" patented technology

Composition for preventing, ameliorating, or treating disease caused by nitration of tyrosine in proteins comprising tyrosine as effective component

A method for ameliorating a disease caused by nitration of tyrosine in protein includes administering a composition comprising tyrosine or a salt thereof to a subject in need thereof. Tyrosine as effective component of the present invention not only can enhance the activity of glutamine synthetase having reduced activity and but also has an effect of restoring the amount (i.e., ratio) of glutamine and glutamic acid in brain and the amount of ammonia to normal level, an effect of enhancing the insulin sensitivity in a model of type 2 diabetes, an effect of suppressing the excitotoxicity and oxidative stress in a model of epileptic seizure, an effect of reducing cerebral infarction and enhancing the activity of GS in a model of brain stroke, an effect of eliminating the nitration of tyrosine using human recombinant MnSOD, and an effect for acute renal failure and hyperammonemia.
Owner:INDUSTRYACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY

Novel ferroptosis inhibitors

PCT designated stageWO2026013195A1Organic active ingredientsNervous disorderMultiple organ dysfunction syndromeLiver disease
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.
Owner:UNIVERSITEIT ANTWERPEN

Novel ferroptosis inhibitors

PCT designated stageWO2026013191A1Nervous disorderOrganic chemistryMultiple organ dysfunction syndromeLiver disease
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein cycle A, R1, R2, and R3 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.
Owner:UNIVERSITEIT ANTWERPEN

Substituted phenothiazines as ferroptosis inhibitors

PendingUS20260109678A1Organic active ingredientsOrganic chemistryMultiple organ dysfunction syndromePhenothiazine
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, and iron metabolism-related disease. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament.
Owner:UNIVERSITEIT ANTWERPEN

Oxazole derivatives for oral administration

PCT designated stageWO2026013198A1Organic active ingredientsNervous disorderIron toxicityLiver disease
The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, and R3 have the same meaning as that defined in the claims and the description, wherein said compound is used as a medicament for oral administration. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as medicament for oral administration in methods of prevention and / or treatment of such diseases.
Owner:UNIVERSITEIT ANTWERPEN

aryl or heteroaryl derivatives

ActiveCN115996910BDiseaseTRPC6
As a compound that can be used as a therapeutic or preventative agent for diseases involving TRPC6, such as nephrotic syndrome, membranous nephropathy, acute renal failure, sepsis, chronic renal failure, diabetic nephropathy, pulmonary hypertension, acute lung injury, heart failure, malignant tumors, and muscular dystrophy, a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided (where Ar... 1 Ar 2 X 1 ~X 3 R 1 R 3 R 7 R 8 and L 1 L 2 (As defined in the instruction manual).
Owner:TEIJIN PHARMA CO LTD